Microarrays in the 2010s: the contribution of microarray-based gene expression profiling to breast cancer classification, prognostication and prediction

Table 2 Multigene predictors of sensitivity to chemotherapy

Authors	Number of cases^a	Regimen	Chemotherapy	Chemosensitivity evaluation	Technology	Method	Signature	NPV	PPV	Accuracy
Chang et al. [116]	24 discovery 6 validation	Neoadjuvant	Docetaxel	Clinical response	cDNA microarray	Supervised	92 genes	83%	92%	88%
Ayers et al. [90]	24 discovery 12 validation	Neoadjuvant	T/FAC	pCR	cDNA microarray	Supervised	74 genes	73%	100% (3/3)	78%
Iwao-Koizumi et al. [91]	44 discovery 26 validation	Neoadjuvant	Docetaxel	Clinical response	High-throughput RT-PCR	Supervised	85 genes	90.9%	73.3%	80.7%
Gianni et al. [70]	89 discovery 92 validation	Neoadjuvant	TA	pCR	qRT-PCR/DNA microarray	Supervised	86 genes	-	-	-
Hess et al. [92]	82 discovery 51 validation	Neoadjuvant	T/FAC	pCR	cDNA microarray	Supervised	30 genes	96%	52%	76%
Thuerigen et al. [93]	52 discovery 48 validation	Neoadjuvant	G-ET	pCR	cDNA microarray	Supervised	512 genes	95%	64%	88%
Farmer et al. [103]	63	Neoadjuvant	FEC	pCR	cDNA microarray	Metagene approach	Stromal metagene	81%	57%	65%

^aNumber of cases in discovery and validation sets. FEC, fluorouracil, epirubicin, and cyclophosphamide; G-ET, gemcitabine, epirubicin, and docetaxel; NPV, negative predictive value; pCR, pathological complete response to neoadjuvant chemotherapy; PPV, positive predictive value; qRT-PCR, quantitative reverse transcriptase-polymerase chain reaction; RT-PCR, reverse transcriptase-polymerase chain reaction; TA, taxanes and anthracycline (that is, paclitaxel and doxorubicin); T/FAC, paclitaxel/fluorouracil, doxorubicin, and cyclophosphamide.

ISSN: 1465-542X